Cargando…

A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation

INTRODUCTION: Recombinant granulocyte colony-stimulating factor (G-CSF) may aid engraftment post high-dose chemo-/radiotherapy in patients with haematological malignancies undergoing allogeneic bone marrow transplantation (BMT); however, the effects of G-CSF on graft-versus-host disease (GvHD), rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ernst, Peter, Bacigalupo, Andrea, Ringdén, Olle, Ruutu, Tapani, Kolb, Hans J, Lawrinson, Susan, Skacel, Tomas
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710993/ https://www.ncbi.nlm.nih.gov/pubmed/19639030 http://dx.doi.org/10.1111/j.1753-5174.2008.00013.x

Ejemplares similares

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Filgrastim, fibrinolysis, and neovascularization
por: Eton, Darwin, et al.
Publicado: (2022)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors
por: Berger, C, et al.
Publicado: (1999)

A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation
por: Ye, Qixiang, et al.
Publicado: (2018)

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
por: Luoma, Sini, et al.
Publicado: (2021)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection
por: Sparrelid, E, et al.
Publicado: (1998)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Sinusitis in patients undergoing allogeneic bone marrow transplantation – a review()
por: Drozd-Sokolowska, Joanna Ewa, et al.
Publicado: (2016)

Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD – A longitudinal study
por: Przybyla, Beata, et al.
Publicado: (2017)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Filgrastim-Associated Pneumonitis in Cancer Patient Undergoing Hematopoietic Stem Cell (HSC) Mobilization for Autologous-HSC Transplantation
por: Patel, Drashti R, et al.
Publicado: (2020)

Filgrastim therapy in a child with neutropenia induced by linezolid
por: Hernández Segurado, Marta, et al.
Publicado: (2013)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: El‐Serafi, Ibrahim, et al.
Publicado: (2019)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

PB2459: AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES OF HAEMATOLOGIC MALIGNANCIES COMPLICATED BY AUTOIMMUNE DISEASES
por: Kang, Ying, et al.
Publicado: (2023)

Long-term safety of filgrastim (rhG-CSF) administration
por: Confer, Dennis L, et al.
Publicado: (2007)

Acute Myocardial Infarction Caused by Filgrastim: A Case Report
por: Bilir, Cemil, et al.
Publicado: (2012)

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
por: Dale, David C., et al.
Publicado: (2017)

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
por: Johannesen, Siw, et al.
Publicado: (2018)

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
por: Halim, Liem Andhyk, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Effect of Filgrastim on adult male rats’ fertility and reproductive performance
por: Saber, Sara Mohamed, et al.
Publicado: (2021)

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003)

Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
por: Islami, Maha M., et al.
Publicado: (2023)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
por: Awan, Farrukh T., et al.
Publicado: (2012)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
por: Hegg, Roberto, et al.
Publicado: (2016)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience
por: Mediwake, Heshani, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0p4rku8go0vfpnvaqto1he3fsc